Ensoma
Ensoma develops one-time in vivo treatments that engineer cells of the hematopoietic system to cure diseases, utilizing its Engenious™ platform to address cancer, autoimmune diseases, and inherited conditions.
Company Overview
Ensoma is a biotechnology company headquartered in Boston, MA, that pioneers in vivo treatments to cure diseases from within by engineering cells of the hematopoietic system. Focusing on a range of conditions including cancer, autoimmune diseases, and inherited disorders, Ensoma leverages its cutting-edge Engenious™ platform.
Engenious™ Platform
Ensoma's Engenious™ platform is an advanced in vivo editing system that allows precise engineering of immune and stem cells. The platform combines innovative delivery technology through a virus-like-particle (VLP) system with a comprehensive DNA editing toolkit. It supports diverse gene modification technologies, including gene replacement, editing, endogenous protein therapies, and regulatory elements, with a payload capacity of up to 35 kilobases.
Therapeutic Focus
Ensoma's pioneering therapeutic approach targets cancer, autoimmune diseases, and inherited conditions. The Engenious™ platform enables in vivo editing of the immune system, enhancing its natural defenses to overcome immuno-suppressive challenges of cancer. The platform's capability for multiplexed combination therapies makes it suitable for addressing complex diseases with tailored solutions.
Recent Financing and Acquisitions
Ensoma has received strong backing from top-tier investors, culminating in $85 million financing and an agreement to acquire Twelve Bio, a gene editing company specializing in CRISPR-Cas technology. This acquisition aims to advance Ensoma's portfolio of in vivo engineered cellular medicines. The company also closed a Series B extension, bringing the total financing round to $135 million.
Innovation and Research
Built on over two decades of academic and clinical research, Ensoma's Engenious™ platform offers unprecedented capabilities for direct transduction of various immune cell types and hematopoietic stem cells. The platform ensures unmatched durability and efficacy through a one-time, off-the-shelf treatment process and eliminates the need for re-dosing, minimizing immunogenicity risks.